Postmarketing study issues were cited as the reason for two recent high-profile withdrawals of cancer drug applications under US Food and Drug Administration review.
For Regeneron Pharmaceuticals, Inc. and Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc), the regulatory path to a supplemental approval for...





